Molecular mechanisms of the microRNA-132 during tumor progressions

Moghbeli, Meysam; Zangouei, Amir Sadra; Navaii, Zahra Nasrpour; Taghehchian, Negin

doi:10.1186/s12935-021-02149-7

Cited by 34 publications

(15 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both miRNAs are involved with oncogenic aspects demonstrating the potential of biomarkers for the screening of different types of cancer. miR-132-3p could be a novel biomarker for screening of hepatocellular, lung, and nasopharyngeal carcinoma, 32 while miR-125b-5p could be the same for lung cancer and breast cancer. 33 The validated target TP53 gene for miR-125b plays a key role in cell death, DNA repair, and cell proliferation, and the overexpression of miR-125b represses the endogenous level of the P53 protein.…”

Section: Discussionmentioning

confidence: 99%

Increased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome

et al. 2022

View full text Add to dashboard Cite

Background and ObjectivesFragile X syndrome (FXS) is a neurodevelopmental disorder, identified as the most common cause of hereditary intellectual disability and monogenic cause of autism spectrum disorders (ASDs), caused by the loss of fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein, a regulator of translation that plays an important role in neurodevelopment, and its loss causes cognitive and behavioral deficits. MicroRNAs (miRNAs) are small molecules that regulate gene expression in diverse biological processes. Previous studies found that the interaction of FMRP with miR-125b and miR-132 regulates the maturation and synaptic plasticity in animal models and miRNA dysregulation plays a role in the pathophysiology of FXS. The present study aimed to analyze the expression of miR-125b-5p and miR-132-3p in the serum of patients with FXS.MethodsThe expressions of circulating miRNAs were studied in the serum of 10 patients with FXS and 20 controls using the real-time quantitative retrotranscribed method analyzed by relative quantification. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were generated to assess the diagnostic values of the miRNAs.ResultsWe found that both miR-125b and miR-132 were increased in the serum of patients with FXS compared with controls and likely involved with FMRP loss. The AUC (95% confidence interval) of miR-125b and miR-132 was 0.94 (0.86–1.0) and 0.89 (0.77–1.0), respectively. Databases allowed for the identification of possible target genes for miR-125b and miR-132, whose products play an important role in the homeostasis of the nervous system.DiscussionOur results indicate that serum miR-125b and miR-132 may serve as potential biomarkers for FXS. The increased expression of circulating miR-125b and miR-132 seems to be associated with the genotype of FXS. Predicted gene targets of the differentially regulated miRNAs are involved in cognitive performance and ASD phenotype.Classification of EvidenceThis study provides Class III evidence that miR-125b and miR-132 distinguish men with FXS from normal controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…MiRNA-132 played role in tumor progression through the regulation of PI3K/AKT and MAPK signaling pathways [33]. MiRNA-132 expression was decreased in studies on lungs cancer cells.…”

Section: The Active Compounds Of Auricularia Polytricha Are Potential...mentioning

confidence: 99%

Auricularia polytricha: A promising medicinal mushroom for combination therapy of colorectal cancer and understanding its potential mechanism of action

Kastanja¹,

Pawestri²,

Firdaus³

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

The Global Burden of Cancer (GLOBOCAN) revealed that there were 1,931,590 new cases and 935,173 deaths due to colorectal cancer in 2020. Treatment for colorectal cancer tends to be invasive and costly. Therefore, further research is needed on non-invasive complementary therapies that are safe and can be used to reduce the probability of recurrence in colorectal cancer patients at an affordable cost. The systematic literature review synthesized resources and presented them in a narrative review. Four databases, including PubMed, Research Gate, ProQuest, and Science Direct, were used to conduct the systematic reviews by following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) criteria. In this review, 36 articles were analyzed descriptively to help describe and summarize the data constructively. The results showed that complementary colorectal cancer therapy with Auricularia polytricha which contains active compounds, such as flavonoids, phenols, and beta-glucans, can increase the expression of miRNA-9, miRNA-217, miRNA-210, miRNA200c, and miRNA-132 which can improve the prognosis of colorectal cancer.

show abstract

“…Conversely, centromeric to miR-22, there are several known tumor suppressor genes, such as miR-212 (Chromosome 17: 2,050,271–2,050,380), miR-132 (Chromosome 17: 2,049,908–2,050,008) and HIC1 (Chromosome 17: 2,054,154–2,063,241), which are all in the same cluster, and are very close to each other, as well as to TP53 (Chromosome 17: 7,661,779–7,687,538) ( Figure 1 ). Particularly, miR-212 and miR-132 are known tumor suppressor miRNAs in various cancers, including lung cancer [ 84 ], hepatocellular carcinoma [ 85 ], prostate cancer [ 86 ], and glioblastoma [ 87 , 88 ].…”

Section: Alterations Of Mir-22 Genementioning

confidence: 99%

An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22

Centomo

Vitiello

Poliseno

et al. 2022

Cancers

View full text Add to dashboard Cite

MiR-22 was first identified as a proto-oncogenic microRNA (miRNA) due to its ability to post-transcriptionally suppress the expression of the potent PTEN (Phosphatase And Tensin Homolog) tumor suppressor gene. miR-22 tumorigenic role in cancer was subsequently supported by its ability to positively trigger lipogenesis, anabolic metabolism, and epithelial-mesenchymal transition (EMT) towards the metastatic spread. However, during the following years, the picture was complicated by the identification of targets that support a tumor-suppressive role in certain tissues or cell types. Indeed, many papers have been published where in vitro cellular assays and in vivo immunodeficient or immunosuppressed xenograft models are used. However, here we show that all the studies performed in vivo, in immunocompetent transgenic and knock-out animal models, unanimously support a proto-oncogenic role for miR-22. Since miR-22 is actively secreted from and readily exchanged between normal and tumoral cells, a functional immune dimension at play could well represent the divider that allows reconciling these contradictory findings. In addition to a critical review of this vast literature, here we provide further proof of the oncogenic role of miR-22 through the analysis of its genomic locus vis a vis the genetic landscape of human cancer.

show abstract

Molecular mechanisms of the microRNA-132 during tumor progressions

Cited by 34 publications

References 135 publications

Increased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome

Increased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome

Auricularia polytricha: A promising medicinal mushroom for combination therapy of colorectal cancer and understanding its potential mechanism of action

An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22

Contact Info

Product

Resources

About